BC
ABOS icon

BIT Capital’s Acumen Pharmaceuticals ABOS Stock Holding History

BIT Capital’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,618
Closed -$55.9K – 122
2023
Q2 		$55.9K Buy
+11,618
New +$55.6K 0.01% 132

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

BIT Capital's ABOS Position: Q3 2023 in Review

BIT Capital sold out of Acumen Pharmaceuticals (ABOS) in Q3 2023, closing a stake of 11,618 shares — an estimated $55.9K sold.

BIT Capital first reported a position in ABOS in Q2 2023 and held it in 1 quarter. The position peaked at $55.9K in Q2 2023. 66 funds tracked by Wall St. Rank hold ABOS as of Q3 2023.

  • BIT Capital reported no remaining Acumen Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • BIT Capital sold 11,618 Acumen Pharmaceuticals shares in Q3 2023, an estimated $55.9K.
  • BIT Capital first reported a position in Acumen Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • BIT Capital's Acumen Pharmaceuticals position peaked at $55.9K in Q2 2023.
  • 66 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2023.

Based on BIT Capital's 13F filing for Q3 2023, filed 12 Feb 2025.